Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) Starts Presentation at NobleCon16
Salarius Pharmaceuticals (NASDAQ: SLRX) is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company’s lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the FDA. Salarius is also developing Seclidemstat for several cancers with high unmet medical need, with a second phase 1 clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma…







